Drug Monograph
Methylprednisolone
Brand names: Medrol, Solu-Medrol, Depo-Medrol
Pharmacokinetic Profile
Plasma Half-Life
1.8–5.2 h (FDA PI)
Biological Half-Life
18–36 h (intermediate)
Metabolism
Hepatic (CYP3A4)
Protein Binding
~77% (albumin only; not transcortin)
Oral Bioavailability
~88%
Volume of Distribution
~1.4 L/kg
Clinical Information
Drug Class
Glucocorticoid (intermediate-acting)
Available Forms
Oral 2–32 mg; IV/IM 40–2000 mg vials
Equivalent Dose
4 mg = 5 mg prednisone
Renal Adjustment
Generally not required
Hepatic Adjustment
Caution; consider lower dose
Pregnancy
Use if benefits outweigh risks
Lactation
Compatible; small amounts in milk
Pediatric Use
Approved across age groups; growth monitoring required
Schedule / Legal Status
Rx only; not controlled
Generic Available
Yes (all formulations)
Boxed Warning
No (FDA class warning for epidural use)
Indications
Methylprednisolone is one of the most broadly indicated synthetic glucocorticoids, used as anti-inflammatory and immunosuppressive therapy across virtually every medical specialty in both adult and pediatric populations. Per the FDA prescribing information, pediatric efficacy and safety are established directly for nephrotic syndrome (children >2 years) and aggressive lymphomas/leukemias (children >1 month); other pediatric indications extrapolate from adult trials given similar disease pathophysiology.
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Severe asthma exacerbation | Adults and children | Adjunctive to bronchodilators | FDA Approved |
| Acute exacerbations of multiple sclerosis | Adults; pediatric extrapolation | Pulse therapy | FDA Approved |
| Idiopathic nephrotic syndrome | Children >2 years (direct evidence); adults | Mono- or pulse for steroid-resistant | FDA Approved |
| Aggressive lymphomas and leukemias | Children >1 month (direct evidence); adults | Adjunctive (chemotherapy backbone) | FDA Approved |
| Rheumatoid arthritis flare / juvenile idiopathic arthritis | Adults and children | Adjunctive to DMARDs | FDA Approved |
| Systemic lupus erythematosus | Adults and children | Mono- or adjunctive | FDA Approved |
| Allergic states (severe; refractory) | Adults and children | Mono- or adjunctive | FDA Approved |
| Adrenocortical insufficiency | Adults and children | Replacement (with mineralocorticoid) | FDA Approved |
| Solid organ transplant rejection | Adults and children | Mono- or adjunctive | FDA Approved |
| Cerebral oedema (CNS tumour) | Adults | Adjunctive | FDA Approved |
| Symptomatic sarcoidosis | Adults | Monotherapy | FDA Approved |
| Inflammatory dermatoses (severe) | Adults and children | Mono- or adjunctive | FDA Approved |
| Acute COPD exacerbation | Adults | Adjunctive | FDA Approved |
| Intra-articular injection (OA, bursitis) | Adults | Local therapy (Depo-Medrol) | FDA Approved |
The choice of formulation reflects the clinical setting. Methylprednisolone sodium succinate (Solu-Medrol) is water-soluble and used IV or IM where rapid onset matters — pulse therapy, anaphylaxis, transplant induction. Methylprednisolone acetate (Depo-Medrol) is a depot suspension for IM or intra-articular injection that provides days-to-weeks of sustained effect; per the manufacturer, it must never be given by intrathecal, epidural, or intravenous routes. Oral methylprednisolone (Medrol) is used for short courses, flare management, and chronic immunosuppression.
Off-label and emerging uses
IVIG-resistant Kawasaki disease (pediatric): IV pulse 30 mg/kg daily for 1–3 days, or 2 mg/kg/day in divided doses. Reduces fever and inflammatory markers more rapidly than a second IVIG dose, although coronary artery aneurysm outcomes are mixed. Evidence: moderate.
Juvenile dermatomyositis: Intermittent IV pulse 20–30 mg/kg/day (max 1 g) for 3 consecutive days, repeated monthly during induction. Evidence: moderate.
Severe COVID-19 (oxygen-requiring): Used as an alternative to dexamethasone in some settings; pulse 250–500 mg has been studied. Evidence: moderate — dexamethasone remains the WHO/NIH-recommended standard.
Bell’s palsy (severe): Short oral course within 72 hours of onset. Evidence: moderate (extrapolated from prednisolone trials).
Acute spinal cord injury: The NASCIS-2/3 high-dose protocols are no longer recommended by AANS/CNS or AAN guidelines. Evidence: low — generally not advised.
IgG4-related disease, autoimmune hepatitis, eosinophilic granulomatosis with polyangiitis: Established off-label use as part of induction regimens. Evidence: moderate.
Croup (moderate–severe): Methylprednisolone is occasionally used, but dexamethasone 0.6 mg/kg PO/IM is the standard of care. Evidence: low for methylprednisolone.
Dosing
The doses below reflect commonly used clinical regimens. Always individualise based on disease severity, response, and the lowest dose that maintains control. Equivalence: 4 mg methylprednisolone ≈ 5 mg prednisone ≈ 0.75 mg dexamethasone ≈ 20 mg hydrocortisone (anti-inflammatory potency).
Adult dosing — by clinical scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Severe asthma exacerbation — adult (ED/ward) | 40–80 mg IV | 40–60 mg PO daily | 125 mg q6h IV | Switch to PO once stable; typical course 5–7 days, no taper if <2 weeks GINA: oral and IV are equivalent in efficacy |
| COPD exacerbation — adult | 40 mg PO daily | 40 mg PO daily × 5 days | 125 mg q6h IV (severe) | GOLD recommends 5-day course; longer courses do not improve outcomes Methylprednisolone is interchangeable with prednisolone |
| Multiple sclerosis relapse — pulse therapy | 1000 mg IV daily | 1000 mg IV × 3–5 days | 1000 mg/day | Infuse over 60–90 min; oral 1000 mg daily is non-inferior (COPOUSEP trial) Routine oral taper after pulse is no longer recommended |
| Anaphylaxis — adjunct (after epinephrine) | 1–2 mg/kg IV | Single dose typically | 125 mg IV | Does not replace epinephrine; aimed at preventing biphasic reaction Onset is too slow for acute airway/circulation |
| SLE flare — moderate | 0.5 mg/kg/day PO | Taper over 4–8 weeks | 1 mg/kg/day | Severe organ involvement: pulse 250–1000 mg IV × 3 days then oral Goal: reach prednisolone-equivalent ≤7.5 mg/day |
| RA flare | 40–80 mg IM (Depo) | As needed (every few weeks) | 120 mg IM single | IM Depo-Medrol provides days–weeks of effect; oral 4–16 mg/day for bridging DMARD therapy must be optimised |
| Solid organ transplant — induction / acute rejection | 500–1000 mg IV | 3–5 day pulse + oral taper | 1000 mg/day | Protocols vary by centre and organ; combine with calcineurin inhibitor + antimetabolite Anti-infective prophylaxis required |
| Cerebral oedema — CNS tumour | 10–20 mg IV bolus | 4 mg q6h IV/PO | 100 mg/day | Dexamethasone is preferred for tumour-related oedema due to lower mineralocorticoid effect Taper as soon as clinically feasible |
| Medrol Dosepak — short oral course (e.g., contact dermatitis, sciatica) | 24 mg PO day 1 | Tapered 4 mg/day over 6 days | 24 mg/day | Pre-packaged 21-tablet (4 mg) dosepak Reserve for short, self-limited inflammatory conditions |
| Intra-articular injection — large joint | 20–80 mg (Depo) | Repeat ≥3 months apart | 80 mg/joint | Knee, shoulder, hip; smaller joints 4–10 mg Limit to 3–4 injections per joint per year |
| Adrenocortical insufficiency | 4–48 mg/day PO | Lowest dose for control | Per response | Hydrocortisone is generally preferred for replacement Add fludrocortisone if mineralocorticoid effect is needed |
Pediatric dosing — by clinical scenario
Pediatric dosing is weight- or BSA-based. The FDA labelling specifies a broad initial range of 0.11–1.6 mg/kg/day (3.2–48 mg/m²/day) divided into three or four doses; the choice within that range is driven by indication and severity rather than age. Pulse therapy in children typically uses 30 mg/kg/day (max 1 g/day) for 3–5 days.
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Severe asthma exacerbation — child ≤12 yr | 1–2 mg/kg IV | 1–2 mg/kg/day PO/IV | 60 mg/day | Divided q12–24h; oral preferred once tolerating PO; 3–10 day course NHLBI recommended dose for asthma uncontrolled by inhaled steroids |
| Severe asthma — adolescent >12 yr | 40–60 mg IV/PO | 40–60 mg/day | 60 mg/day | Adult-equivalent dosing once weight ≥40 kg No taper if course <1 week and on inhaled steroid |
| Adherence-limited asthma (IM Depo-Medrol) | 7.5 mg/kg IM (≤4 yr) | 240 mg IM × 1 (>4 yr) | 240 mg single dose | Reserve for vomiting or non-adherence; not a substitute for daily controller therapy Acetate formulation only; never IV |
| Acute MS relapse — pediatric | 30 mg/kg/day IV | 30 mg/kg × 3–5 days | 1000 mg/day | Infuse over 60–90 min; oral taper rarely needed Same regimen used for paediatric ADEM and NMOSD relapses |
| Steroid-resistant nephrotic syndrome (>2 yr) | 15 mg/kg or 500 mg/m² IV | Daily × 3–5 days, then taper | 1000 mg/dose | For children failing 4+ weeks of oral prednisolone before biopsy First-line is oral prednisolone 60 mg/m²/day (KDIGO 2025) |
| IVIG-resistant Kawasaki disease | 30 mg/kg IV pulse | Once daily × 1–3 days, OR 2 mg/kg/day divided q8h × 5–7 d then taper | 1000 mg/dose | Used after failure of two IVIG doses; co-managed with paediatric cardiology CAA outcomes vary; benefits weighed individually |
| Juvenile dermatomyositis — induction | 20–30 mg/kg/day IV | 3 consecutive days, monthly × 7–9 cycles | 1000 mg/day | Combined with methotrexate or mycophenolate per JDM protocols IV pulse improves absorption when nailfold capillary loss limits oral PK |
| Pediatric SLE — severe organ involvement | 30 mg/kg/day IV pulse | 3 days, then PO 1–2 mg/kg/day taper | 1000 mg/day pulse | Used for lupus nephritis, neuropsychiatric SLE, severe haemolytic anaemia Always with steroid-sparing agent (MMF, cyclophosphamide) |
| Anaphylaxis — pediatric adjunct | 1–2 mg/kg IV | Single dose | 125 mg/dose | After epinephrine, fluids, antihistamine; aim is to reduce risk of biphasic reaction No replacement for first-line epinephrine |
| Juvenile idiopathic arthritis — systemic flare | 10–30 mg/kg/day IV pulse | 3 days; bridge to DMARD/biologic | 1000 mg/day | Macrophage activation syndrome may require pulse + cyclosporine Intra-articular triamcinolone preferred for oligoarticular JIA |
| Pediatric maintenance / chronic immunosuppression | 0.11–1.6 mg/kg/day PO | Lowest dose for control | Per response | Equivalent 3.2–48 mg/m²/day; review necessity at every visit due to growth suppression Alternate-day dosing may reduce growth impact |
Population-specific adjustments
| Population | Adjustment | Rationale |
|---|---|---|
| Renal impairment | No specific adjustment; methylprednisolone is dialyzable | Hepatic metabolism predominates; renal excretion of unchanged drug 1–9% |
| Hepatic impairment | Use lowest effective dose; monitor closely | Reduced clearance can prolong exposure and exaggerate effects |
| Elderly (≥65 y) | Use lowest effective dose; aggressive bone and BP monitoring | Greater risk of osteoporosis, hypertension, infection, and delirium |
| Pediatric — key cautions | Use lowest effective dose; alternate-day where feasible; monitor height | Linear growth and HPA-axis suppression are the major paediatric-specific harms |
| Obese pediatric patient | Consider dosing on ideal or adjusted body weight; cap at adult max | Mg/kg dosing without cap can produce supratherapeutic exposure |
| Pregnancy | Use if maternal benefit outweighs fetal risk | Crosses placenta less than dexamethasone; preferred for treating maternal disease |
| Lactation | Compatible; consider waiting 4 hours after high doses (≥40 mg) | Small amounts in breast milk; clinical effects on infant unlikely at standard doses |
Tapering nuance
A taper is required only when therapy has continued long enough to suppress the HPA axis — typically more than 2–3 weeks of supraphysiologic dosing (roughly >20 mg methylprednisolone/day in adults, or any chronic dose above physiological requirement in children). Short courses can be stopped abruptly. For chronic users, taper by 10–20% of the current dose every 1–2 weeks, slowing as the dose approaches physiologic equivalent. Stress-dose coverage is required for surgery, trauma, or severe illness in any patient on supraphysiologic doses for >3 weeks within the past year.
Pharmacology
Mechanism of action
Methylprednisolone is a synthetic 6-α-methyl derivative of prednisolone with approximately five-fold greater anti-inflammatory potency than cortisol and minimal mineralocorticoid activity. After diffusing into target cells, it binds the cytosolic glucocorticoid receptor (GR), inducing receptor dimerisation and translocation to the nucleus. There it modulates transcription through two principal mechanisms — transrepression of pro-inflammatory transcription factors (NF-κB, AP-1) and transactivation of anti-inflammatory genes (annexin-1, IκB, MKP-1).
The downstream effects include reduced cytokine production (IL-1, IL-2, IL-6, TNF-α), suppressed phospholipase A2 activity, decreased prostaglandin and leukotriene synthesis, redistribution of lymphocytes out of the circulation, and inhibition of fibroblast proliferation. Non-genomic effects mediated through membrane-bound GRs explain the rapid clinical response seen with high-dose pulse therapy — within hours rather than the 24–48 hours required for full transcriptional effects.
ADME profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability ~88%; Tmax ~48 minutes. Sodium succinate IV: peak within minutes; onset of effect within 1 hour. Acetate IM: sustained release over 1–4 weeks. | Oral and IV can be used interchangeably at 1:1 ratio in non-critical settings; acetate is unsuitable for emergencies. |
| Distribution | Vd ~1.4 L/kg; protein binding ~77% to albumin only. Unlike cortisol and prednisolone, methylprednisolone does not bind transcortin (CBG), giving it linear, dose-independent kinetics. | Hypoalbuminaemia raises the free fraction; consider lower doses in advanced liver disease or severe nephrotic syndrome. Predictable PK simplifies titration vs prednisolone. |
| Metabolism | Hepatic via CYP3A4 to inactive metabolites (6β-hydroxymethylprednisolone, 20-carboxymethylprednisolone); also a P-glycoprotein substrate. | Strong CYP3A4 inhibitors and inducers cause large changes in exposure; review interactions before initiating. |
| Elimination | Plasma t½ 1.8–5.2 h (FDA PI); biological t½ 18–36 h (intermediate). Total clearance ~5–6 mL/min/kg. Renal excretion of unchanged drug 1–9%. | Once-daily morning dosing is feasible for chronic therapy; renal impairment does not require dose reduction; the drug is dialyzable. |
Side Effects
Adverse effects are predominantly dose- and duration-dependent, and the spectrum applies similarly to children and adults — though linear growth suppression, behavioural changes, and accelerated bone loss are particularly relevant in paediatrics. Frequencies below are drawn from systematic reviews of glucocorticoid therapy and pivotal MS-pulse and transplant trials; absolute incidence varies widely by indication, daily dose, and cumulative exposure. Short courses (<2 weeks) carry markedly lower risk than chronic supraphysiologic dosing.
≥10%Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Insomnia | 30–50% | More likely with evening dosing; advise once-daily morning administration |
| Increased appetite / weight gain | 20–40% | Cumulative dose is the strongest predictor; counsel on diet at initiation |
| Mood / behavioural changes (irritability, lability, mild euphoria) | 15–30% | Particularly noticeable in children — schools and parents should be alerted before starting |
| Hyperglycaemia | 10–30% | Higher in patients with pre-existing diabetes or pre-diabetes |
| Fluid retention / oedema | 10–20% | Less than with prednisone due to lower mineralocorticoid effect |
| Dyspepsia / heartburn | 10–25% | Routine PPI prophylaxis is not indicated unless other risk factors |
| Acne / facial flushing | ~15% | Common during pulse therapy and in adolescents; reversible after taper |
1–10%Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hypertension | 5–15% | Average BP rise 5–10 mm Hg; check at every follow-up |
| Hypokalaemia | 5–10% | More common with high-dose pulse and concurrent diuretics |
| Bruising / skin thinning | 5–15% | Cumulative-dose effect; counsel on skin care for long-term users |
| Cushingoid features (moon face, central adiposity) | 5–10% | Develops over weeks–months; partly reversible after discontinuation |
| Menstrual irregularities | ~5% | Reversible; reassure unless persistent after taper |
| Hyperhidrosis | ~5% | Especially with pulse therapy |
| Headache | ~5% | Usually self-limited; persistent or severe headache warrants further evaluation |
| Glucose intolerance (new-onset) | 2–5% | Risk rises with cumulative dose >1.5 g; check HbA1c at 3 months |
SeriousSerious / Important Adverse Effects
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Adrenal suppression / crisis on withdrawal | High after >3 weeks supraphysiologic dose | After taper or stress event | Slow taper; stress-dose coverage; AM cortisol if uncertain |
| Linear growth suppression (pediatric) | Significant with >3 months supraphysiologic use | Months | Plot height/weight every 3–6 months; alternate-day dosing where feasible; refer to endocrinology if velocity falls |
| Serious bacterial, viral, or fungal infection | Relative risk ~2× at >10 mg prednisone-equivalent/day | Days–months | PJP prophylaxis if high-dose >4 weeks; screen for latent TB, HBV; vaccinate before therapy |
| Severe varicella / measles (immunosuppressed children) | Rare but life-threatening | Days after exposure | Post-exposure VZIG or IVIG; urgent IV acyclovir for varicella; never give live vaccine on high-dose therapy |
| Glucocorticoid-induced osteoporosis / fragility fracture | Up to 30–50% with long-term use | Weeks–months; rapid early loss | Calcium + vitamin D for all; bisphosphonate per ACR 2022 guideline at moderate–high fracture risk |
| Hyperglycaemia / new-onset diabetes | ~5–25% (population-dependent) | Days–weeks | Check fasting glucose at baseline; HbA1c at 3 months; insulin or oral agents as needed |
| Avascular necrosis (hip, shoulder, knee) | ~1–5% (higher with cumulative dose >2 g) | Months–years | MRI for new joint pain; orthopaedic referral if confirmed |
| Steroid psychosis / severe mood disturbance | ~2–6% (higher at >40 mg/day) | First 1–2 weeks | Reduce dose if possible; antipsychotic if severe; psychiatric referral |
| Peptic ulcer / GI bleed (with NSAIDs) | 2–4× increase with concomitant NSAIDs | Variable | Avoid NSAIDs where possible; PPI prophylaxis if combined |
| Posterior subcapsular cataract | ~10–30% with chronic use | Months–years | Annual ophthalmology review for chronic users (adults and children) |
| Open-angle glaucoma / raised IOP | ~5% develop steroid response | Weeks–months | Baseline and periodic IOP if chronic therapy or family history of glaucoma |
| Anaphylaxis or severe hypersensitivity (to product) | Rare | Minutes–hours after first exposure | Discontinue permanently; epinephrine, supportive care; document allergy |
| Tumour lysis syndrome (haematologic malignancies) | Rare overall; higher in lymphoma/leukaemia | First 1–3 days of therapy | Hydration, allopurinol or rasburicase; monitor electrolytes |
| Cardiac arrhythmia / sudden CV collapse (high-dose IV pulse) | Very rare | During or shortly after rapid infusion | Infuse 1 g doses over ≥30–60 min; monitored setting and resuscitation available |
DiscontinuationDiscontinuation / Treatment-Limiting Effects
Long-term Use (≥3 months)
~10–15% discontinue or switch
Top reasons: intolerable Cushingoid features, severe hyperglycaemia, mood disturbance, infection. In children, growth concerns are an additional driver.
Pulse Therapy (e.g., MS, transplant)
~2–5% terminate course
Top reasons: severe insomnia, mood/psychosis, hyperglycaemia requiring inpatient management.
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Cushingoid features / weight gain | ~5% | Most common reason in chronic users; consider switching to steroid-sparing agent |
| Uncontrolled hyperglycaemia | 2–5% | Often drives reduction or cross-cover with insulin rather than full discontinuation |
| Severe mood disturbance / psychosis | 1–3% | Often higher in patients with prior psychiatric history |
| Serious infection | 1–3% | May require dose reduction, prophylaxis, or temporary hold |
| Growth failure (pediatric) | 1–2% (chronic users) | Triggers transition to alternate-day dosing or steroid-sparing therapy |
| Insomnia (refractory) | 1–2% | Mostly with pulse therapy; rarely a chronic-use stopping reason |
Highest-yield management point — adrenal suppression
Any patient who has received methylprednisolone >20 mg/day (adult) or any chronic supraphysiologic paediatric dose for more than 2–3 weeks (or repeated short courses) within the last 12 months should be assumed to have HPA-axis suppression. Stress-dose hydrocortisone (50–100 mg IV every 6–8 hours in adults; 50 mg/m² in children) is required for surgery, trauma, sepsis, or major illness, and the patient should carry a medical alert card. Rapid withdrawal can precipitate adrenal crisis with hypotension, hypoglycaemia, hyponatraemia, and shock.
Drug Interactions
Methylprednisolone is metabolised primarily by CYP3A4, so its plasma levels are markedly affected by inhibitors and inducers of that enzyme. It also has clinically important pharmacodynamic interactions through immunosuppression, GI mucosal injury, and effects on potassium and glucose handling. Major interactions are listed first.
MajorLive vaccines (MMR, varicella, BCG, yellow fever, intranasal flu, rotavirus)
MechanismImmunosuppression allows replication of attenuated organism
EffectRisk of disseminated infection from vaccine strain; reduced vaccine efficacy
ManagementAvoid during and ≥1 month after stopping high-dose therapy (≥20 mg/day prednisone-equivalent for ≥14 days, or ≥2 mg/kg/day in children)
FDA PI / IDSA / AAP Red BookMajorStrong CYP3A4 inhibitors (clarithromycin, itraconazole, ritonavir)
MechanismInhibition of methylprednisolone metabolism
EffectUp to 3-fold increase in AUC; risk of Cushingoid effects with chronic use
ManagementReduce dose by ~50%; consider azithromycin instead of clarithromycin
Lexicomp / FDA PIMajorStrong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, phenobarbital)
MechanismAccelerated hepatic metabolism
EffectUp to 60% reduction in steroid exposure; loss of disease control
ManagementIncrease methylprednisolone dose 1.5–3× and titrate to clinical effect
Lexicomp / FDA PIMajorNSAIDs (ibuprofen, naproxen, etc.)
MechanismAdditive injury to GI mucosa via prostaglandin inhibition
Effect2–4 fold increase in peptic ulcer / GI bleed risk
ManagementAvoid combination if possible; PPI prophylaxis when unavoidable; consider acetaminophen
Lexicomp / Meta-analysisMajorFluoroquinolones (ciprofloxacin, levofloxacin)
MechanismAdditive tendon toxicity
EffectIncreased risk of tendinitis and rupture, especially Achilles, in patients >60
ManagementUse alternative antibiotic when feasible; counsel on tendon symptoms
FDA Boxed Warning (FQ)MajorWarfarin
MechanismVariable; both inhibition and potentiation reported
EffectUnpredictable INR change; bleeding risk increased by GI mucosal effects
ManagementCheck INR within 3–7 days of starting/stopping or any major dose change
Lexicomp / Case reportsModerateLoop / thiazide diuretics
MechanismAdditive potassium loss
EffectHypokalaemia, especially with high-dose pulse therapy
ManagementMonitor K⁺ at baseline and during therapy; supplement as needed
FDA PIModerateInsulin and oral hypoglycaemics
MechanismSteroid-induced hyperglycaemia opposes glucose-lowering effect
EffectLoss of glycaemic control, sometimes severe
ManagementAnticipate insulin dose increases (often 20–40%) at initiation; intensify monitoring
LexicompModerateCyclosporine / tacrolimus
MechanismMutual CYP3A4 competition; complex bidirectional effect
EffectIncreased exposure of both agents; additive immunosuppression and toxicity
ManagementRoutine in transplant; monitor calcineurin inhibitor levels and renal function closely
FDA PI / Transplant guidelinesModerateBisphosphonates
MechanismPharmacodynamic — bisphosphonate offsets glucocorticoid bone loss
EffectBeneficial: prevents glucocorticoid-induced osteoporosis
ManagementIndicated for adults at moderate–high fracture risk on ≥2.5 mg/day for ≥3 months (ACR 2022)
ACR 2022 GIOP GuidelineModerateAspirin (high-dose)
MechanismGlucocorticoids increase salicylate clearance; reverse on withdrawal
EffectRisk of salicylate toxicity when steroid is tapered if aspirin dose unchanged
ManagementMonitor salicylate levels in patients on chronic high-dose aspirin
FDA PIMinorGrapefruit juice
MechanismIntestinal CYP3A4 inhibition
EffectModest increase in oral methylprednisolone exposure (~30%)
ManagementCounsel against large daily intake; clinically minor for most patients
Pharmacokinetic studyMonitoring
Monitoring intensity scales with dose and duration. Short courses (<2 weeks) require minimal lab follow-up beyond glucose and BP checks; chronic supraphysiologic dosing demands a structured surveillance plan covering metabolic, infectious, ocular, and skeletal complications. In children, linear growth is the additional priority.
-
Blood pressure
Baseline, then every visit
Routine Glucocorticoids raise BP via fluid retention and vascular tone changes. Treat new hypertension per standard guidelines (or paediatric BP percentiles in children). -
Weight and BMI
Baseline, then every visit
Routine Track to detect Cushingoid changes early. Counsel on dietary measures and refer to dietitian if cumulative gain >5–10% of baseline. -
Linear growth (height) — pediatric
Every 3–6 months on chronic therapy
Routine Plot on standard growth charts; calculate height velocity. Falling off the curve (>1 z-score drop) prompts dose review, alternate-day dosing, or steroid-sparing strategy. Refer to paediatric endocrinology for sustained growth failure. -
Fasting glucose / HbA1c
Baseline; then 1, 3, and 6 months for chronic use
Routine High-risk patients (BMI ≥30, family history, pre-diabetes) need earlier rechecks at 1–2 weeks. Fingerstick monitoring is appropriate for inpatient pulse therapy. -
Serum potassium
Baseline + during pulse therapy
Trigger-based Routinely required only for high-dose IV pulse, concurrent diuretics, or symptoms (cramps, palpitations). Replace if K⁺ <3.5 mmol/L. -
Bone mineral density (adult)
Baseline if >3 months expected; repeat 1–2 years
Routine Per ACR 2022 GIOP guideline: calcium 1000–1200 mg + vitamin D 600–800 IU; pharmacotherapy (oral/IV bisphosphonate, denosumab, or anabolic agent) for adults at medium–high fracture risk on ≥2.5 mg/day for ≥3 months. -
Bone health (pediatric)
Baseline DXA if planned chronic use
Routine Use age- and sex-matched z-scores. Optimise calcium/vitamin D and weight-bearing exercise. Bisphosphonates are reserved for children with documented vertebral fracture or low BMD per paediatric endocrinology. -
Ophthalmology review
Baseline if planning >3 months; annually thereafter
Routine Includes IOP and posterior subcapsular cataract screening — applies to children too. New visual symptoms warrant urgent referral. -
Latent TB / HBV screening
Before starting chronic therapy
Routine IGRA + HBV serology in all chronic users, especially at >15 mg prednisone-equivalent/day or with other immunosuppressants. Treat latent TB before high-dose initiation. -
PJP prophylaxis assessment
If >20 mg prednisone-equivalent/day for >4 weeks (adults); or >0.4 mg/kg/day in children
Trigger-based TMP-SMX in age/weight-appropriate doses; especially if combined with other immunosuppressants or in haematologic malignancy. -
Varicella / measles immunity
Before chronic therapy in children
Routine Check serology; vaccinate non-immune children ≥4 weeks before starting immunosuppressive doses where possible. Counsel parents on post-exposure protocols. -
AM cortisol / ACTH stimulation
When considering withdrawal after >3 weeks supraphysiologic use
Trigger-based Useful when uncertain about HPA recovery during taper. Cosyntropin stimulation is the gold standard; AM cortisol <3 µg/dL suggests suppression, >15 µg/dL suggests intact axis. -
Mood / mental state / behaviour
Every visit
Routine Specifically ask about insomnia, irritability, mania, depression, suicidal ideation. In children, ask about school behaviour, sleep, and emotional outbursts. -
Joint pain (chronic high-dose)
As reported
Trigger-based New-onset hip, shoulder, or knee pain after weeks of therapy should prompt MRI to evaluate for avascular necrosis, especially with cumulative dose >2 g methylprednisolone.
Contraindications & Cautions
Absolute contraindications
- Systemic fungal infection — except for amphotericin-resistant adrenal involvement; immunosuppression worsens infection.
- Hypersensitivity to methylprednisolone or any excipient (lactose, polyethylene glycol).
- Live or live-attenuated vaccines at immunosuppressive doses (≥20 mg prednisone-equivalent for ≥14 days in adults; ≥2 mg/kg/day in children).
- Intramuscular injection in immune thrombocytopenic purpura (ITP) — risk of haematoma at injection site.
- Intrathecal administration — never indicated; risk of arachnoiditis and neurological injury.
- Intravenous administration of methylprednisolone acetate (Depo-Medrol) — must never be given IV; the depot suspension is for IM, intra-articular, or intralesional use only.
- Cerebral malaria — high-dose IV pulse increases mortality (large RCT data).
Relative contraindications (specialist input recommended)
- Active or latent tuberculosis — treat latent infection before starting; coordinate with infectious disease for active TB.
- Active peptic ulcer disease or recent GI bleeding — treat the ulcer first; PPI cover and avoidance of NSAIDs essential if therapy is unavoidable.
- Active herpes infection of the eye — risk of corneal perforation; ophthalmology must guide use.
- Severe psychiatric disease, including prior steroid psychosis — co-management with psychiatry; consider lower dose or alternative.
- Recent myocardial infarction — high-dose IV has been linked to ventricular wall rupture; reserve for clear indication.
- Strongyloides infection (endemic exposure) — risk of life-threatening hyperinfection; screen and treat first.
- Non-immune child with recent varicella or measles exposure — provide post-exposure VZIG/IVIG and consult ID; chickenpox in immunosuppressed children can be fatal.
Use with caution
- Diabetes mellitus — anticipate dose adjustments to glucose-lowering therapy.
- Heart failure / hypertension — fluid retention may worsen control even though mineralocorticoid effect is modest.
- Osteoporosis or high fracture risk — initiate calcium, vitamin D, and consider bisphosphonate from the outset (per ACR 2022).
- Glaucoma — IOP can rise; ophthalmology review at baseline.
- Diverticulitis or recent bowel anastomosis — masking of perforation symptoms; raise the threshold for imaging.
- Hypothyroidism or cirrhosis — exaggerated steroid effect due to reduced metabolism.
- Pregnancy (third trimester) — risk of cleft lip/palate is small; benefits usually outweigh risks for active disease.
- Children — long-term use suppresses linear growth; review necessity at every visit and minimise duration.
FDA Class-Wide Regulatory Warning
Serious neurologic events with epidural injection (April 2014)
The FDA issued a Drug Safety Communication for all injectable corticosteroids — including methylprednisolone, hydrocortisone, triamcinolone, betamethasone, and dexamethasone — warning that epidural administration may result in rare but serious adverse events, including loss of vision, stroke, paralysis, and death. Methylprednisolone acetate (Depo-Medrol) is not FDA-approved for epidural use and the manufacturer has stated it must not be given intrathecally, epidurally, or intravenously. Particulate corticosteroids carry a higher theoretical risk of vascular embolism than non-particulate dexamethasone. Clinicians performing image-guided epidural steroid injections should follow current professional society guidance.
FDA Class-Wide Regulatory Warning
Adrenal suppression and abrupt withdrawal
All systemic corticosteroids carry a class-wide warning regarding HPA-axis suppression. Abrupt discontinuation after prolonged supraphysiologic dosing can precipitate adrenal crisis. Patients on long-term therapy require gradual taper, stress-dose coverage during major illness or surgery, and a medical alert card describing their steroid use.
Patient Counselling
Purpose of therapy
Methylprednisolone is a powerful anti-inflammatory and immune-suppressing medication. Used for short periods, it can rapidly bring an asthma attack, allergic reaction, or arthritis flare under control. Used for longer periods, it controls serious autoimmune diseases and prevents transplant rejection. The same properties that make it effective also cause its side effects, so the goal is always the lowest dose that keeps the underlying condition controlled.
How to take
Take oral methylprednisolone once daily in the morning, with food. Morning dosing matches the body’s natural cortisol rhythm and reduces insomnia. Never stop taking it suddenly if you have been on it for more than a few weeks — your body’s ability to make its own cortisol may have been turned down, and stopping abruptly can cause dangerous low blood pressure and weakness. Carry information that you are taking a steroid, and tell every doctor and dentist who treats you. If you are due to have surgery, an injury, or a major illness, the dose may need to be increased temporarily.
Concerns to discuss with patients (and families)
Insomnia and “wired” feeling
Tell patientDifficulty sleeping is common, especially at higher doses. Take the full dose in the morning. Avoid caffeine after midday, and use a regular sleep routine. Most people improve once the dose is reduced.
Call prescriberIf sleep is impossible for several nights in a row, or if you feel agitated, racing thoughts, or unusually irritable.
Increased appetite and weight gain
Tell patientHunger increases on steroids, particularly for sweet and starchy foods. Plan meals ahead, focus on lean protein and vegetables, and limit added sugar. Some weight gain is expected with longer courses.
Call prescriberIf weight gain is rapid (more than 2–3 kg in a week) or if you develop swelling in the ankles or shortness of breath.
Mood changes
Tell patientYou may feel more emotional, irritable, or unusually upbeat. These changes usually settle as the dose comes down. Family members may notice the changes before you do — listen to their feedback.
Call prescriberUrgently if you have thoughts of harming yourself, severe depression, paranoia, hallucinations, or feel out of touch with reality.
Risk of infection
Tell patientSteroids reduce your ability to fight infection and may also mask the usual signs (fever, pain). Avoid contact with people who have chickenpox, shingles, or measles unless you are immune. Stay up to date on inactivated vaccines (flu, pneumococcal, COVID), but do not have live vaccines while on a high dose.
Call prescriberSame day for any new fever, severe sore throat, productive cough, painful urination, painful skin rash, or contact with chickenpox or shingles.
Children on steroids — for parents
Tell parentLong courses can slow your child’s growth, so the doctor will measure height regularly and use the lowest dose that controls the disease. Behavioural changes (irritability, mood swings, difficulty sleeping) are common — tell the school. Inactivated vaccines are safe; live vaccines (MMR, varicella, nasal flu, BCG, rotavirus) need to be discussed before they are given. Notify the doctor immediately if your child is exposed to chickenpox or measles.
Call prescriberSame day for new fever, exposure to chickenpox/measles, persistent vomiting, rapid weight gain, or new behavioural concerns. Urgently for any signs of poor growth, severe abdominal pain, or sudden weakness during a taper.
High blood sugar
Tell patientSteroids raise blood sugar. If you have diabetes, you may need more insulin or tablet doses while on this medication. Even without diabetes, blood sugar can rise — particularly during pulse therapy.
Call prescriberFor excessive thirst, frequent urination, blurred vision, or — if you check sugars — readings repeatedly above 250 mg/dL (14 mmol/L).
Stomach upset and ulcer risk
Tell patientTake with food to reduce stomach irritation. Avoid ibuprofen, naproxen, and similar pain medicines while on steroids — use acetaminophen for pain instead unless your prescriber has told you otherwise.
Call prescriberUrgently for black or tar-like stools, vomiting blood or coffee-ground material, or sudden severe abdominal pain.
Bone and joint health
Tell patientLong-term steroids can thin the bones. Take calcium and vitamin D as recommended. Weight-bearing exercise and stopping smoking help. Your doctor may suggest a bone density scan and possibly bone-protecting medication.
Call prescriberFor new persistent pain in the hip, groin, knee, or shoulder, or for any sudden back pain that could indicate a fracture.
Stopping the medication
Tell patientNever stop suddenly if you have been taking it for more than 2–3 weeks. Follow the tapering schedule exactly. If you miss a dose, take it as soon as you remember on the same day, but do not double up.
Call prescriberIf you develop weakness, dizziness on standing, severe fatigue, nausea, or low blood pressure during a taper — these may indicate adrenal insufficiency and need urgent assessment.
Sources
Regulatory (PI / SmPC / FDA Communications)
- Pfizer. Medrol (methylprednisolone tablets) prescribing information. labeling.pfizer.com Primary US prescribing information for oral methylprednisolone covering pharmacokinetics (plasma t½ 1.8–5.2 h), pediatric dosing range (0.11–1.6 mg/kg/day), warnings, and adverse reactions.
- Pfizer. Solu-Medrol (methylprednisolone sodium succinate for injection) prescribing information. labeling.pfizer.com Reference for IV/IM dosing, reconstitution, pediatric efficacy data (nephrotic syndrome, lymphoma/leukemia), and pulse-therapy administration.
- Pfizer. Depo-Medrol (methylprednisolone acetate injectable suspension) prescribing information. accessdata.fda.gov Reference for depot intramuscular and intra-articular use; explicitly states the suspension must not be given by intrathecal, epidural, or IV routes.
- U.S. Food and Drug Administration. Drug Safety Communication: FDA requires label changes to warn of rare but serious neurologic problems after epidural corticosteroid injections. April 23, 2014. fda.gov Underpins the regulatory warning on epidural use of all injectable corticosteroids, including methylprednisolone acetate.
Key Clinical Trials
- Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326(9):581–588. doi.org/10.1056/NEJM199202273260901 Landmark trial establishing IV methylprednisolone (not oral prednisone) for acute optic neuritis and shaping the modern MS-relapse pulse regimen.
- Le Page E, Veillard D, Laplaud DA, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015;386(9997):974–981. doi.org/10.1016/S0140-6736(15)61137-0 Demonstrates non-inferiority of oral 1 g methylprednisolone vs IV for MS relapse — supports outpatient management.
- Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. NASCIS-2. N Engl J Med. 1990;322(20):1405–1411. doi.org/10.1056/NEJM199005173222001 Historical basis for high-dose methylprednisolone in acute SCI; now superseded by safety concerns and updated guidance.
- Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016;10:CD001446. doi.org/10.1002/14651858.CD001446.pub5 Negative trial evidence informing decisions in non-MS demyelinating disease.
- Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics. 2012;129(1):e17–e23. doi.org/10.1542/peds.2011-1148 Randomized evidence supporting IV methylprednisolone pulse for IVIG-resistant Kawasaki disease.
Guidelines
- Humphrey MB, Russell L, Danila MI, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken). 2023;75(12):2405–2419. doi.org/10.1002/acr.25240 Current ACR guideline updating fracture-risk thresholds and treatment options (bisphosphonates, denosumab, parathyroid hormone analogues, romosozumab) for adults on ≥2.5 mg/day prednisone-equivalent for ≥3 months.
- KDIGO Workgroup. KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. kdigo.org Pediatric nephrotic syndrome guideline confirming oral prednisolone 60 mg/m² (or 2 mg/kg) as first-line, with IV methylprednisolone pulse reserved for steroid-resistant disease.
- National Heart, Lung, and Blood Institute. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma. nhlbi.nih.gov Source for paediatric asthma exacerbation dosing (1–2 mg/kg/day, maximum 60 mg/day).
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. ginasthma.org Source for systemic corticosteroid dosing and duration in asthma exacerbations across age groups.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD. goldcopd.org Supports the 5-day, 40 mg prednisolone-equivalent course recommended for COPD exacerbations.
Mechanistic / Basic Science
- Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50(11):3408–3417. doi.org/10.1002/art.20583 Authoritative review of genomic and non-genomic glucocorticoid mechanisms underlying the rapid effect of pulse therapy.
- Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954–963. doi.org/10.1093/clinids/11.6.954 Original meta-analysis quantifying infection risk by daily and cumulative dose, still cited in current guidance.
Pharmacokinetics / Special Populations
- Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98. doi.org/10.2165/00003088-200544010-00003 Reference review providing the PK parameters and equivalent-dose conversions cited in the ADME and dosing sections.
- Möllmann H, Rohdewald P, Barth J, Verho M, Derendorf H. Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. Biopharm Drug Dispos. 1989;10(5):453–464. doi.org/10.1002/bdd.2510100503 Confirms the dose-linear pharmacokinetics of methylprednisolone — a clinically useful contrast with prednisolone, which has saturable transcortin binding.
- Tornatore KM, Logue G, Venuto RC, Davis PJ. Pharmacokinetics of methylprednisolone in elderly and young healthy males. J Am Geriatr Soc. 1994;42(10):1118–1122. doi.org/10.1111/j.1532-5415.1994.tb06219.x Pharmacokinetic data informing dose considerations in older adults.
- Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42–52. doi.org/10.1002/cpt.377 Methodology underlying current LactMed guidance on glucocorticoid use during breastfeeding.